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Introduction
Pre-eclampsia is a syndrome that is characterized by an inability of the trophoblast to invade the decidual arteries leading to alterations in placental development, placental perfusion and an insufficient transport of nutrients (Odegard et al., 2000) . It is a major cause of maternal and fetal morbidity and mortality (Jarvenpaa et al., 2007) and affects 7-10% of pregnancies (Zhou et al., 1997; Red-Horse et al., 2004) .
The precise etiology of pre-eclampsia is unknown, probably because it is a syndrome of heterogeneous origin (Odegard et al., 2000) . Although many factors impact pre-eclampsia, including some not yet identified, recent evidence suggests an association with impaired angiogenesis (Rajakumar et al., 2001; Stepan et al., 2006; Rana et al., 2007) , as well as changes in local oxygen tension (Roberts and Gammill, 2005) , and immunological alterations in the early placental microenvironment (Redman and Sargent, 2005; Roberts and Gammill, 2005; Sargent, Borzychowski, and Redman, 2006) . The early success of a pregnancy relies on appropriate implantation and placentation (Red-Horse et al., 2004; Sargent et al., 2006) . Changes or alterations in these two events can cause a number of immediate or longer-term problems including infertility, spontaneous miscarriage, intrauterine growth restriction or preterm birth, in addition to pre-eclampsia. For instance, deficient implantation may lead to infertility, whereas if placentation is inappropriate, first trimester pregnancy loss or second or third trimester growth restriction, may result. Pre-eclampsia resulting from placental dysfunction alters maternal systems (Sargent et al., 2006) , progressing through a pre-clinical stage (early placental developmental arrest) to a clinical stage (deficiencies in late placental development). These placental inadequacies contribute to hypoxic conditions and cause the maternal manifestations of the disease: hypertension, proteinuria, coagulopathy and hepatic dysfunction (Redman and Sargent, 2005) .
We intend to provide a comprehensive review of the early immunological events that participate in implantation and placentation and that may be adversely modulating these events leading to preeclampsia, which differs from other recent work published in this journal (Guerin et al., 2009) . Although this review intends to cover some of the most important aspects of the immune system found in the origins of pre-eclampsia, it focuses more on the regulatory and specific immunological factors involved. Therefore, and because they would require lengthier discussions, some components of the immune system that may also play an important role in its etiology, such as specific glycoproteins, other cytokines and monocytes and macrophages, will not be discussed in this review.
In the pre-eclampsia syndrome, one of the most important observations that supports a diminished placental perfusion is poor vascular remodeling of the uterine spiral arteries that irrigate the intervillous space (Roberts and Gammill, 2005) . Normal vascular remodeling is achieved by the migration of the differentiated cytotrophoblast. From the eighth week of gestation, two different villous cytotrophoblastic precursors exist which are programmed to differentiate into separate subpopulations (James et al., 2005) : (i) the syncytiotrophoblast, which is formed by the merging of villous trophoblasts, and (ii) the extravillous trophoblast, which is invasive and passes through the syncytiotrophoblast and forms the extravillous columns (Aplin, 1991) . The extravillous trophoblast consists of all the trophoblast located outside the placental villi. It is highly migratory, proliferative and invasive (Zhou et al., 1997) .
The cytotrophoblasts that differentiate into the invasive phenotype express new membrane-bound molecules, among them the chemokine receptor, CCR10 (Sato et al., 2003) , and adhesion molecules. In pre-eclampsia, the cytotrophoblast does not acquire the vascular adhesion phenotype since it cannot express the adhesion molecules characteristic of the differentiated and invasive extravillous cytotrophoblast [aVb3, a1b1, VE-cadherin/CD144, VCAM-1 (vascular cell adhesion molecule-1)/CD106 and PECAM-1 (platelet endothelial cell adhesion molecule-1)/CD31], and it maintains the phenotype of the cytotrophoblast of the proximal column region expressing a6b4, aVb6 and E-cadherin/CD324 (Zhou et al., 1997) . This contributes to altered trophoblast invasion and the failure of vascular remodeling in pre-eclampsia (Roberts and Gammill, 2005) .
The invasion of cytotrophoblasts involves, in addition to vascular adhesion, a physical approximation of these cells to the extracellular matrix, the degradation of this matrix and their subsequent migration (Lyall, 2006) . In order to degrade the extracellular matrix, matrix metalloproteinases (MMPs) are required. MMPs 1, 2, 3, 9 and 14 participate in the invasion of trophoblasts in normal human pregnancy (Huppertz et al., 1998; Bai et al., 2005) with MMP-9 being the most abundant due to greater expression during weeks 3-9 of human gestation (Bai et al., 2005) . In pre-eclampsia, the cytotrophoblasts are deficient in MMP-9 production and also have decreased expression of MMP-1 and MMP-7 (Lyall, 2006) . The nuclear transcription factor that mediates the signaling of the MMP-3, MMP-9 and MMP-13 genes, ETS2 [v-ets erythroblastosis virus E26 oncogene homolog 2 (avian)], is considered essential for normal placental function (Yamamoto et al., 1998) , although no reports have so far demonstrated a deficiency in MMP production due to inappropriate expression of ETS2 in pre-eclampsia.
In normal human pregnancies, the differentiation and invasion processes of trophoblasts are regulated by the paracrine factors, activin and transforming growth factors-b (TGF-b). Activin A stimulates the invasive potential of placental cytotrophoblasts. However, since the in vivo expression of activin by the trophoblast is low, it is more likely that the activin that stimulates the trophoblast is derived from maternal tissues. On the other hand, TGF-b isoforms, which are mainly inhibitors of trophoblast growth, are co-expressed with their receptors by the cytotrophoblast (Jones et al., 2006) . TGF-b1 and TGF-b2 are present in the decidua (Simpson et al., 2000) , whereas the extravillous trophoblast expresses solely TGF-b2 (Lyall et al., 2001) . TGF-b3 is present only in cells of the immune system, and it is expressed in large concentrations in cases of placental pathology (Jones et al., 2006) . TGF-b1 may diminish MMP-9 production, and increase the expression of epithelial cadherin and b-catenin through the signal-transducing protein, Smad2 (Zhao et al., 2006) . TGF-b3 inhibits trophoblast invasion because it inhibits MMP production, and it has been found in higher concentrations in human pre-eclamptic placentas (Caniggia et al., 1999 ). An inhibitory effect of TGF-b2 on trophoblast growth has not been reported (Jones et al., 2006) .
The various inhibitory actions of TGF-b isoforms on trophoblast differentiation have been attributed to endoglin, which is an accessory protein for TGF-b1 and TGF-b3 receptors, but not for TGF-b2 receptors (St-Jacques et al., 1994) . The placenta produces a soluble co-receptor for TGF-b1 and TGF-b-3, soluble endoglin (sEng) (Venkatesha et al., 2006) , which is increased in patients with pre-eclampsia (Levine et al., 2006) . Soluble endoglin is considered to be an anti-angiogenic protein. The mechanisms influencing basic vascular remodeling are described in Fig. 1 .
Search method
A computerized scientific literature search was performed using EBSCO, OVID, Medline and Highwire databases. The search was focused on immune system cells, cytokines and molecules that participate in the activation and regulation of the immune system, and may be participating in early pregnancy events that lead to the development of pre-eclampsia. The search was limited only to immunological factors related to the origins of pre-eclampsia, and specifically to the most important cytokine and cellular aspects that modulate trophoblast differentiation. We did not include all cytokines and cells of the immune system in our search because some of them were beyond the range of this review and would require a longer discussion. The most relevant literature was selected and divided into themes.
The role of the immune system in the origin of pre-eclampsia Several investigators believe that poor invasion by trophoblasts can be ascribed to an aberrant maternal immune response against the trophoblast. Indeed, it is probable that low oxygen tension and underexpressed angiogenic factors are secondary to immunological alterations observed in this syndrome. Sargent et al. (2006) propose that the pre-eclampsia syndrome is a disease in which there are two stages: the first is poor invasion by trophoblasts as a result of inadequate expression of HLA-G leading to a diminished stimulation of decidual NK cells which participate in the production of immunoregulatory cytokines and angiogenic factors. The second stage is characterized by a systemic inflammatory response involving leukocytes and endothelium. This inflammatory stimulus appears to originate in the placenta, and may be caused by the release of necrotic and/or apoptotic syncytiotrophoblasts into the maternal circulation.
The role of the immune system in the development of preeclampsia involves more than HLA-G and NK cells, since T CD4
+ T cells, dendritic cells (DCs), receptors, adhesion molecules and cytokines also participate. Knowledge of the mechanisms which lead to the development of fetal or cytotrophoblast tolerance by the maternal immune system in normal pregnancy is required to understand which components of the immune system may be involved in the responses leading to poor trophoblast invasion in pre-eclamptic women. The pathways in which the immune system may be involved leading to inadequate implantation in pre-eclampsia and further appearance of hypertension are proposed in Fig. 2 . Herewith, we will describe how the many components of the immune system (cells, cytokines and molecules) participate in the origins of pre-eclampsia, either because they produce certain effectors (e.g. cytokines), or because they modulate immune responses or Figure 1 In the first weeks of gestation, physiological hypoxia promotes trophoblast proliferation. Next, these trophoblasts differentiate into an invasive phenotype acquiring chemokine receptors (e.g. CCR1), cell adhesion molecules (aVb3, a1b1, VE-cadherin, VCAM-1, PECAM-1), and the ability to secrete metalloproteinases (MMPs 1, 2, 3, 7, 9 and 14). The invasive cytotrophoblast then migrates, preceding the formation of the placental villi and becoming the extravillous cytotrophoblast, whereby it participates in the remodeling of the uterine spiral arteries. The early antecedents to pre-eclamptic disease include maintaining the proliferative phenotype of the trophoblast, preventing its differentiation into an invasive phenotype, or blocking its capacity to migrate. These are further promoted by the persistence of low oxygen tensions and the presence of TGF-b1, TGF-b3 and IFN-g. Green arrows and lines describe progressive events and stimulatory or promoting factors; and red lines describe inhibitory factors.
because they have shown an altered function that promotes the development of this disease.
The role of NK cells in pre-eclampsia
Placental NK cells differ from peripheral NKs and therefore have been designated as uterine NK (uNK) cells . uNK cells are present in the decidua during the first and second trimesters and participate in the modification of the uterine arteries promoting increased blood flow to the feto-placental unit (Moffett-King, 2002) . These cells, due to their direct contact with the trophoblast, play an important role in the acceptance and rejection of the fetus , and they may be influenced by the steroid hormones, estrogens and progesterone (Dosiou and Giudice, 2005) .
Maternal decidual NK cells can be found around the infiltrating trophoblasts and it has been proposed that they modulate trophoblast invasion in a dose-dependent manner (Hu et al., 2006) . uNK cells are a source of decidual IFN-g during early human pregnancy and likely participate in the inhibition of extravillous trophoblast invasion (Lash et al., 2006) . Indeed, it has been observed that the inhibition of cytotrophoblast migration is contact-independent and occurs through the induction of changes in the expression of MMP-2 and plasminogen activator inhibitor-1 production through IFN-g (Hu et al., 2006) . There is some controversy regarding the role of IFN-g in the inhibition of cytotrophoblast migration which will be addressed later.
In order to be able to recognize other cells, to be activated and to discriminate between target and non-target cells, NK cells have receptors that mediate activation or inhibition. These are divided into three families: KIRs [killer immunoglobulin (Ig)-like receptors], CD94/NKGs (lectin family receptors) and ILTs (Ig-like transcripts or 'leukocyte immunoglobulin-like receptors'; Lopez-Botet and Bellon, 1999) . KIRs recognize MHC class Ia molecules (HLA-A, B, C), whereas the heterodimeric inhibitory receptor, CD94-NKG2A, binds class Ib major histocompatibility molecules (specifically HLA-E) (Caligiuri, 2008) . ILT receptor ligands will be addressed further on.
The expression and role of MHC molecules on the trophoblast
The invasive extravillous cytotrophoblast expresses only class I MHC molecules, predominantly HLA-E, F and G , but it has also been reported that first trimester human extravillous trophoblast expresses HLA-C (King et al., 2000) , a polymorphic histocompatibility molecule. These HLA-C molecules bind to KIR2D receptors of decidual NK cells. Mothers who do not display activating KIRs when the fetal trophoblast expresses HLA-C2 molecules are at higher risk of developing pre-eclampsia (Hiby et al., 2004) .
The HLA-F molecule is barely detectable in the first trimester, but its expression increases as pregnancy advances, whereas HLA-G is expressed throughout the course of pregnancy (Shobu et al., 2006) . HLA-E has been found in all the cells that have any form of HLA-G or HLA-F, and it is localized mainly to the surface of the extravillous Figure 2 Activation of select immune system cells alters secretion of cytokine profiles that lead to the maternal syndrome of pre-eclampsia. Initially these adverse events cause persistent placental hypoxia then inadequate placentation, etc. The pathological cytokine profiles may be due to an alteration in immune system regulation, or an inadequate fetal allorecognition, or to inflammatory triggers present during implantation.
Immune system participates in origins of pre-eclampsia trophoblast that invades the maternal decidua. The extravillous trophoblast is the first cell in which the expression of three non-classical HLA antigens has been identified simultaneously (Ishitani et al., 2003) .
Although both HLA-G and HLA-E inhibit NK cells when bound to the CD96/NKG2 receptor (Soderstrom et al., 1997; Lee et al., 1998) , the exact function of HLA-F is unknown, although HLA-E and HLA-F could promote fetal growth since their expression coincides with the period of rapid fetal growth (Shobu et al., 2006) .
HLA-G molecules are very important in the modulation of the human maternal immune system during pregnancy, and therefore in the acceptance of the semi-allogenic fetus (Hviid, 2006) . The factors that regulate specific up-regulation of these molecules are poorly understood. HLA-G expression is induced in an autonomous manner by the cells, more so than by microenvironment signals, since HLA-G is present in ectopic pregnancies and placental accretion where there is no contact with the decidua (Goldman-Wohl et al., 2000) . A unique characteristic of the HLA-G genes is that they code for multiple isoforms as a result of alternative splicing, which leads to the production of seven HLA-G transcripts of which HLA-G5 and G6 are secreted proteins, also known as sG1 and sG2, respectively (Hunt et al., 2005) . Their soluble forms, also known as sHLA-G, may trigger apoptosis of activated CD8 + T cells (Solier et al., 2002) among other functions. sHLA-G isoforms are localized in all placental trophoblasts, including the villous trophoblast and the syncytiotrophoblast, whereas the membrane-bound HLA-G molecules are found only in extravillous trophoblasts (Ishitani et al., 2003) and in human maternal choriodecidual cells in a low but consistent manner (Blanco, 2008) . The association between the genetics of HLA-G and pre-eclampsia supports the pathogenic role of HLA-G in this disease (Hviid, 2006) , since a primiparous woman whose fetus carries the HLA-G +14 bp/+14 bp genotype will have a higher risk of developing preeclampsia. It is speculated that this phenotype may predispose to preeclampsia due to an aberrant and probably reduced expression of HLA-G in the placenta (Hylenius et al., 2004) . In addition to the presence of the 14-bp HLA-G sequence, the G*0106 allele may also contribute to the development of pre-eclampsia (Moreau et al., 2008) . Some investigators suggest that the expression of HLA-E, F and G in pre-eclamptic placentas is not different from that of normal placentas (Shobu et al., 2006) . However, many other studies have demonstrated a diminished HLA-G mRNA or HLA-G protein expression in term placentas of pre-eclamptic patients (Hara et al., 1996; GoldmanWohl et al., 2000) ; specifically, a deficit in HLA-G3 transcripts has been associated with mild pre-eclampsia (O'Brien et al., 2001) .
ILT receptors
Most MHC class I molecules, including HLA-G, bind receptors of the ILT receptor family, although with different affinities (Lopez-Botet and Bellon, 1999) . The ILT4 receptor is expressed predominantly on the surface of human myelomonocytic cells, whereas ILT2 is present in many cells of the immune system including T cells, NK cells (Shiroishi et al., 2003) and B cells (Colonna et al., 1997) . Both ILT2 and ILT4 bind HLA-G with 3-4 times greater affinity than classic Ia histocompatibility molecules (Shiroishi et al., 2003) . HLA-G molecules inhibit NK-mediated lysis through ILT receptors (Hviid, 2006) , because both ILT4 and ILT2 have immunoreceptor tyrosine-based inhibitory receptor motifs in their cytoplasmic domains. In addition, since these receptors compete for the MHC class I molecules with the CD8 + T lymphocyte, they could be inhibiting the activation of this cell (Shiroishi et al., 2003) . An important role of HLA-G appears to be the modulation of the behavior of macrophages, monocytes and DCs in pregnancy through the ILT4 receptor (Allan et al., 1999) . The presence and physiology of ILT receptors in pre-eclampsia is yet to be described.
The role of IFN-g and other cytokines
Normal pregnancy trophoblast displays insensitivity to interferons (IFNs), possibly a mechanism to promote feto-placental survival. This insensitivity is due to a lesion in IFN signal transduction (predominantly IFN-a) in the trophoblast owing to a lack of expression of proteins related to the transcription factor, ISGF-3 (IFN-stimulated gene factor-3). This may be one of the reasons the normal trophoblast does not express classical polymorphic HLA antigens, such as HLA-A and HLA-B (Cross et al., 1999) , and only HLA-C molecules have been found in extravillous trophoblast (King et al., 1996) . Since IFN-g is an inhibitor of trophoblast invasion in addition to a promoter of the expression of classical MHC class I molecules, it would be important to know whether these alterations that lead to IFN resistance in the normal trophoblast are present in the trophoblast of patients who develop pre-eclampsia. Evidence shows that INF-g inhibits the migration of human cytotrophoblasts in explant cultures in a NK dose-dependent manner (Hu et al., 2006) , and it is found in high levels in pre-eclamptic women (Arriaga-Pizano et al., 2005; Banerjee et al., 2005; Murphy et al., 2009) . However, its role during normal pregnancy is still controversial. For instance, primiparous, but not multiparous, IFN-g knockout mice experience fetal loss (Ashkar and Croy, 1999) , and this cytokine can trigger spiral artery modifications (Monk et al., 2005) . It is important to note that IFN-g is not produced only by decidual NK cells; there are other cells that also produce this cytokine, which suggests that its production may be modulated by other mediators involved in pre-eclampsia.
IL-12 is another cytokine that represses human cytotrophoblast proteases in an IFN-g-dependent manner and up-regulates other inhibitors, such as tissue inhibitor of metalloproteinases-1, in an IFN-g-independent manner (Karmakar et al., 2004) .
Monocytes of pre-eclamptic patients spontaneously synthesize greater amounts of IL-1b, IL-6 and IL-8 (Luppi and DeLoia, 2006) . TNF-a and IL-16 are also increased in pre-eclamptic women compared with normal patients (Benyo et al., 2001; Gu et al., 2008) . TNF-a is associated with the increase in CD68
+ cells in the preeclamptic decidua in humans, and since TNF-a and IL-1b induce the production of monocyte chemotactic protein-1 in decidual cells, they promote the persistence of macrophages at the implantation site and probably participate in the poor endovascular invasion of the trophoblast observed in pre-eclampsia (Lockwood et al., 2006) . A cytokine that contributes to protecting the fetus from rejection during pregnancy is IL-10. IL-10 produced by the trophoblast is able to activate HLA-G expression in trophoblasts in the feto-maternal interface and in monocytes, an effect that is selective for these MHC class I molecules (Moreau et al., 1999) . IL-10 levels are decreased both in placenta and in serum of women with preeclampsia (Hennessy et al., 1999; Makris et al., 2006) . The lowered levels of IL-10 in this disease have been associated with the 1082G allele of the IL-10 gene, which is more frequently found in preeclamptic patients (Kamali-Sarvestani et al., 2006) , and to an AA genotype in the promoter region of IL-10 in the placenta (Makris et al., 2006) . These could be considered as genetic susceptibility factors for the development of pre-eclampsia.
As mentioned, pre-eclampsia is a two-stage disease, thus it is important to clarify that many cytokines could be involved in the pathophysiology of both stages. However, due to the limitations of studying early human pregnancy events, the patterns in serum cytokines found in pre-eclamptic patients have frequently been extrapolated backwards to the possible origins of the disease. In this review, we infer that the patterns of serum IFN-g levels found in preeclamptic patients could be related to the origin of the disease, since it has been reported that IFN-g blocks trophoblast invasion (Hu et al., 2006) , one of the early alterations seen in the placentation process of patients who develop pre-eclampsia.
The Th1/Th2 paradigm and its relationship with pre-eclampsia For many years, the model of immune regulation during pregnancy has been based on a shift of the maternal immune response from Th1 toward a Th2 response (Lin et al., 1993; Saito et al., 1999; Tsuda et al., 2001 ). This model is based on the observation that in a nonpregnant woman, the response that elicits an antigen presented to a Th0 lymphocyte will depend, in part, on the cytokine microenvironment in which this lymphocyte is present. For instance, a cytokine microenvironment rich in IL-12, IL-18 and IFN-g will favor the production of Th1 cells that secrete TNF-a, IL-2 and IFN-g and promote activation of other cells such as macrophages, cytotoxic T lymphocytes, etc. On the other hand, a microenvironment rich in IL-10 and IL-4 will promote the production of Th2 lymphocytes. Th1 cytokines inhibit Th2 responses, and vice-versa. In healthy nonpregnant women, there is a balance between Th1 and Th2 responses (Sargent et al., 2006) . However, in pregnancy, this balance is significantly altered by the presence of the placenta, since the progesterone and cytokines it produces modulate the immune cells via the Th2 response (Piccinni et al., 2000) .
It has been proposed that in pre-eclampsia the shift toward Th2 probably does not occur, or it is reverted in very early stages of the disease. In consequence, Th1 responses are not suppressed and IFN-g production is normal (Sargent et al., 2006) . As noted previously, in women with pre-eclampsia, the cytokine profiles in peripheral blood are mainly Th1, showing an increase in IFN-g and a decrease in IL-4 (Arriaga-Pizano et al., 2005). As well, there are decreased levels of IL-10 in serum and placenta in these patients (Hennessy et al., 1999) . Th2 cells are predominant in the second and third trimesters in normal pregnancy, whereas Th1 subpopulations are most common in pre-eclamptic patients (Saito et al., 1999) .
It should be emphasized that the concept of Th1/Th2 responses in pregnancy appears to be rather simplistic since the precise nature of the changes in the cytokine profiles is still controversial (Hviid, 2006) .
Chaouat et al. have addressed the limitations of the Th1/Th2 paradigm in pregnancy since IFN-g cannot be, by itself, the decisive element because this cytokine is required at low doses for vascular development and the transformation of the uterine spiral arteries necessary for normal implantation. Since normal implantation requires the participation of certain inflammatory responses, this paradigm could be over-simplified, especially in pregnancy diseases. Therefore, the role of NK cells and other cytokines, such as IL-12, IL-8, etc., secreted by immune cells and by other cells should also be considered (Chaouat et al., 2004) .
Other cytokines also modulate Th1/Th2 responses, such as the TGF-b cytokine family, which has been implicated in Th1/Th2 regulation, although its exact role remains controversial (Conboy et al., 1997) . Prior to studies in knockout mice, it was thought that the three mammalian isoforms of TGF-b (1, 2 and 3) had redundant functions. New evidence has shown that although they participate in a diversity of biological functions, each subtype plays particular roles in immune system regulation (Ingman and Jones, 2008) . In mouse studies, TGF-b2 promotes Th1 cell development in the presence of high concentrations of IL-2 (Hoehn et al., 1995) and IL-4 (Lingnau et al., 1998) . Conversely, Wen et al. have shown in human bronchial epithelial cells that IFN-g antagonizes the release of TGF-b2, but it also blocks TGF-b1 to a lesser extent (Wen et al., 2002) . However, it is unknown whether IFN-g has an effect on TGF-b3. Although the traditional view is that IFN-g and TGF-b are mutually inhibitory in human placenta, solid evidence regarding their roles in the origin of pre-eclampsia is still lacking. Clearly more work is needed to reveal the complex cytokine interactions involved during implantation and placentation.
The role of regulatory T lymphocytes T CD4
+ lymphocyte subpopulations are not limited any longer to the Th1 and Th2 cells, since regulatory T (Treg) and Th17 cells have been the focus of many recent investigations involving normal pregnancies and pregnancy-related pathologies.
As mentioned previously, a predominance of Th2 cytokines has been considered an important mechanistic determinant for the survival of the fetus. However, since knockout mice with quadruple deletions of Th2 cytokine genes (IL-4, IL-5, IL-9 and IL-13) have normal pregnancies, we now know that Th2 cytokines are not essential for fetal survival in the allogeneic murine pregnancy (Fallon et al., 2002) . This suggests that products of other cells, and not necessarily Th2 lymphocytes, must regulate Th1 alloreactive cells in pregnancy. They could, perhaps, be modulated by Treg lymphocytes (Zenclussen, 2006) . Regulatory T cells are CD4 + lymphocytes that constitutively express CD25 and the Foxp3/FOXP3 gene, which is the master control gene for the development and natural function of Tregs. These cells have been the center of attention in recent studies since they play an important role in the maintenance of self-tolerance and in the negative control of pathological and physiological immune responses (Fehervari and Sakaguchi, 2004) . Tregs also participate in mediating human maternal tolerance to the fetus Guleria and Sayegh, 2007) , whereas abundant numbers of T Immune system participates in origins of pre-eclampsia CD4 + CD25 bright lymphocytes, which express high levels of CD152
[also called CTLA-4 (cytotoxic T lymphocyte antigen 4)/CD152], have been found in human decidua during pregnancy. The proportion of these cells is significantly lower in spontaneous miscarriages compared with those of induced abortions (Sasaki et al., 2004) . In normal pregnancy, a high percentage of lymphocytes isolated from the decidua have the regulatory phenotype (i.e. are Tregs), whereas in peripheral blood of these same women there are fewer Tregs than in non-pregnant women. This suggests a preferential recruitment of Treg cells toward the feto-maternal interface where they can contribute to the regulation of local fetus-specific responses (Tilburgs et al., 2008) .
The Zenclussen et al. reported that administration of Treg cells diminishes abortion in mice prone to abort. Interestingly, the levels of the Th1 cytokines, IFN-g and TNF-a, in the decidua did not diminish after administration, and there were no increases in Th2 cytokines such as IL-10 and IL-4. This suggests that although Tregs can promote a tolerance microenvironment at the feto-maternal interface in mice, they can neither prevent high levels of Th1 cells nor induce an increase in Th2 cells . Tregs, therefore, promote tolerance at this level by activation of alternate pathways, and not necessarily by promoting a shift in cytokine production by the immune system cells (Zenclussen, 2006) . This could be particularly applicable to pre-eclampsia where the cytokine profiles are deviated toward the Th1 phenotype.
Do Th17 lymphocytes participate in pre-eclampsia?
Th17 lymphocytes represent a recently described subpopulation of T CD4 + cells which in mice protect against extracellular bacteria but also lead to autoimmune disorders. Their properties in humans are only partially known. Th17 cells originate from CD4 + and CD161 (Bettelli et al., 2006) . Additionally, combined IL-1b plus IL-23 stimulation is necessary for the activation of these cells (Cosmi et al., 2008) . Annunziato et al. (2007) found, in Crohn's disease patients, the presence of Th17 cells, which, besides producing IL-17, had the capacity to secrete IFN-g (Th17/Th1 clones). Both Th17 and Th17/Th1 clones selectively express IL-23R, CCR6 and RORgt, but they exhibit little susceptibility to the regulation of autologous Tregs. Therefore, Th17 lymphocytes share characteristics of Th1 and Th17 cells and can be activated by IL-12. Very little is known regarding the role of Th17 cells in pregnancy disorders including pre-eclampsia, but the intriguing possibility that lymphocytes with the Th17 or Th17/Th1 phenotypes could be involved, should be considered. A preliminary report by SantnerNanan et al., (2008) suggests that in the third trimester of pregnancy in women with pre-eclampsia, there might be a bias toward Th17 cells (Guerin et al., 2009) . It would be interesting to know whether DCs or activation by IL-12 could lead to the promotion of Th17/Th1 cells in this pathology.
Negative co-regulatory molecules: their participation in immune control in pregnancy
In order to activate a T cell, it is required that its receptor (TCR) recognizes a peptide portion of MHC molecules followed by a co-stimulatory signal provided by one or more surface molecules on the antigen-presenting cell (APC; Sharpe and Abbas, 2006) . However, some co-regulatory immune molecules, instead of delivering activation signals, provide negative or inhibitory signals. Typically, these molecules are inducible and expressed after activation in order to halt immune responses . The prototype negative co-stimulatory molecule is CTLA-4, which is expressed in the tissues of the feto-maternal interface throughout gestation (Kaufman et al., 1999) . Another co-regulatory pathway that is important in the maintenance of peripheral tolerance involves the PDR and PDL (programmed death receptors and their ligands), PD-L1 and PD-L2 (Khoury and Sayegh, 2004) . PD-L1 is expressed in parenchymal and hematopoietic cells and in activated lymphocytes where it regulates tolerance and autoimmunity. PD-L2 is restricted to macrophages and DCs (Keir et al., 2006) . In pregnancy, PD-L1 (also known as B7-H1) is constitutively expressed by the human syncytiotrophoblast and the extravillous trophoblast and is strategically positioned to protect the fetal cells from the mother's activated leukocytes (Petroff et al., 2003) . Since blockade of PD-L1 results in a significant increase in IFN-g producing lymphocytes in the murine placenta, and PD-L1-deficient mice have lower fetal survival rates than controls and exhibit activated Th1 responses in vivo, it can be concluded that PD-L1 plays an important role in tolerance to the allogenic fetus in mice (Guleria et al., 2005) . PD-L1 is related to the Treg lymphocytes in the induction of feto-maternal tolerance because Tregs also express PD-L1. Actually, the effect of PD-L1 in pregnancy is possibly mediated by CD25
+ Tregs, and this concept is supported by the fact that Tregs in PD-L1 deficient mice are the same as controls in terms of numbers, phenotype, and placental traffic but they are incapable of inhibiting alloreactive Th1 cells in vitro (Habicht et al., 2007) .
Immune system modulation by DCs and their relationship with pre-eclampsia
DCs respond to signals from the tissue microenvironment, and at the mucosa they acquire characteristics or phenotypes that are necessary to regulate local specific immune responses. They are considered to be the immune system 'guardians' of the uterine mucosa, capable of inducing tolerance under normal physiologic conditions (Blois et al., 2007) . Subpopulations of DCs exist that differ in phenotype, function and microenvironment localization (Pulendran et al., 2001) (Banchereau et al., 2000) . These precursors appear to be an important source of type I IFNs in response to viral and other stimuli (Pulendran et al., 2001 to peripheral blood. DCs in the decidua produce less IL-12 than DCs in peripheral blood, and decidual myeloid DCs induce a higher percentage of Th2 lymphocytes. This suggests that DCs in the decidua may be regulating the Th1/Th2 balance and promoting a Th2 state, thereby favoring a normal pregnancy (Miyazaki et al., 2003) . Some investigators have reported that 'lymphoid' or plasmacytoid DCs induce high levels of Th1 cytokines such as IFN-g and IL-2, but very little or no Th2 type cytokines. 'Myeloid' DCs, in contrast, induce high amounts of Th2 cytokines, such as IL-4 and IL-10, in addition to producing IFN-g and IL-2 (Pulendran et al., 1999) . Although true for the decidua, these observations cannot be extrapolated to the placenta since the decidua has a higher number of myeloid DCs that induce Th2 cells (Miyazaki et al., 2003) . It is likely that the state of activation of the DC in pregnancy may be more important that the lineage or subtype of DCs in terms of displaying a Th1 or Th2 phenotype (Blois et al., 2007) . Two hypotheses have been proposed to explain how DCs maintain peripheral tolerance. One suggests that both functions of DCs, which are to promote tolerance and induce immunity, are not in conflict with each other because they are induced under different circumstances. Since self-antigens bind to and activate DCs under physiological conditions, they induce tolerance, whereas antigens bound by DCs in the context of activation stimuli lead to activation of T lymphocytes.
This hypothesis presumes a steady, immature state of tolerogenic DCs (Hawiger et al., 2001; Steinman, 2001; Blois et al., 2007) . But this concept has been recently challenged, since it was demonstrated that mature DCs induce Treg lymphocytes in vivo, which implies that there must exist maturation signals, both tolerogenic and immunogenic, for DCs. It is proposed that the induction of tolerance happens when partial or semi-maturation occurs, and that complete maturation of DCs is immunogenic (Lutz and Schuler, 2002) .
On the other hand, investigators who support the second hypothesis propose that it is the unique subtype of DCs which is responsible for the induction of tolerance (Reid et al., 2000) . Whether it is due to different maturation stages or to subpopulations of DCs of different ontogenies, the tolerogenic function of DCs is important since it not only controls immunity, but actively participates in the maintenance of tolerance to self-antigens (Groux et al., 2004) .
There is growing evidence that interactions between DCs and Treg lymphocytes play critical roles in maintaining the balance between immune responses and tolerance. Not only is the state of maturation of the DCs regarded as important for the induction of peripheral tolerance through the modification of the state of activation of T cells, but also that different subtypes or functional status of the DCs are involved in promoting Treg differentiation (Hubert et al., 2007) .
Another interesting observation is that human decidual DCs are in close contact with CD16
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/CD56
+ /ICAM3 + NK cells (Kammerer et al., 2003) . Very little is known regarding the possible interactions between decidual DCs and NK cells in resting conditions, but it has been shown that the dialogue between immature DCs and resting NK cells leads to cellular activation in the presence of microbial stimuli (Blois et al., 2007) . NK cells may activate DCs, and pathophysiological conditions might exist in which an imbalance in the proportion of uNK and DCs results in aberrant activation of DCs and disturbance of the course of pregnancy. This pertains since the cytokine patterns secreted by the activated DCs influence the polarization of T cell responses (Blois et al., 2007) . Type I IFNs, specifically IFN-b, also influence human DC behavior, as stimulation by IFN-b during their maturation promotes the generation of Th1, IFN-g producing lymphocytes, in part through the expression of cytokines from the IL-12 family by the DCs. In contrast, contact with IFN-b by mature DCs prevents the shift toward Th1 lymphocytes and their cytokines (Nagai et al., 2003) .
A transitory increase in CD8A + uterine DCs has been reported in early pregnancy in mice together with a decrease in the number of IL-10 producing DCs. This suggests that in early gestation, fetal antigens might be stimulating uterine DCs to produce Th1 cytokines and are therefore contributing to the inflammatory characteristics of the microenvironment during implantation (Blois et al., 2007) . Afterwards, the transitory presence of IFN disappears and a Th2 cytokine profile is established with regulatory IL-10, which predominates during the three trimesters and mediates the maternal immune response in murine pregnancy (Lin et al., 1993) . This supports the findings of Sargent et al. (2006) in relation to the Th1/Th2 paradigm. The shift toward a Th2 phenotype probably does not happen or is reverted in early stages of human pregnancy so that Th1 responses are not suppressed and IFN-g production is normal in pre-eclampsia. More studies addressing the phenotype and function of human DCs in preeclampsia are needed in order to elucidate the role(s) of these cells,
Immune system participates in origins of pre-eclampsia and the corresponding changes in cytokine profiles particular to this pathology.
The role of indoleamine 2,3-dioxygenase Indoleamine 2,3-dioxygenase (IDO) is an enzyme that degrades tryptophan, consequently generating metabolites from this amino acid, and thereby inhibiting cell proliferation, including that of activated T lymphocytes (Curti, 2008) . IDO is expressed by villous and extravillous trophoblasts in humans (Mellor and Munn, 2004) where it inhibits activation of maternal T lymphocytes by tryptophan deprivation . By decreasing (in a reversible manner) the tryptophan concentration below the level required for T lymphocyte proliferation, IDO causes the lymphocyte to arrest its cellular cycle, but not to become apoptotic (Kudo et al., 2001) . It has been reported that serum tryptophan concentrations are decreased in the first trimester of normal human pregnancies (Schrocksnadel et al., 1996) . In pre-eclampsia, in contrast, higher concentrations of serum tryptophan have been reported along with a decrease in IDO activity which could contribute to the pathogenesis of pre-eclampsia and the higher concentrations of serum tryptophan in the mother (Kudo et al., 2003) . The cause for the diminished activity of IDO in pre-eclampsia is not yet clear. Both IL-4 and TGF-b are capable of decreasing IDO expression; however, it is uncertain whether these cytokines are causal in the pre-eclamptic placenta (Kudo et al., 2003) . IDO may also have an indirect effect on the immune response by affecting the function of some APCs, such as the DCs, by increasing the expression of suppressor ligands (e.g. PDL1 or CD95), by triggering the secretion of immunoregulatory cytokines (e.g. IL-10 or TGF-b; Guleria and Sayegh, 2007) , or by modulating the expression of HLA-G in DCs (Lopez et al., 2006) .
Treg lymphocytes, when binding their CTLA-4 with the B7 molecules of the DCs and monocytes from decidua and peripheral blood in normal pregnancies, increase IDO activity in these cells through the induction of IFN-g (Kudo et al., 2001; Miwa et al., 2005) . However, this leads to a paradox, since although this enzyme may be induced by IFN-g, pre-eclampsia is a Th1 phenotype with elevated levels of IFN-g. Therefore, there should be increased IDO activity associated with this pathology, but the opposite is the case in pre-eclampsia. Guerin reports that a decrease in IDO activity may be caused by, and at the same time act as, a promoting factor of diminished Treg cell function (Guerin et al., 2009) . Hence, it becomes important to explore this issue further to learn how IDO activity is regulated and the source(s) and mechanisms of action of the responsible factors.
Could damage-and pathogen-associated molecular patterns participate in the origins of pre-eclampsia?
Molecules known as damage-associated molecular pattern proteins (DAMPs) are proinflammatory factors of unspecific immunity (Foell et al., 2007) . DAMPs can be considered markers of inflammation mediated by phagocytes (Foell et al., 2007) and by other cell types since they are released by activated or injured cells in stress conditions (Oppenheim and Yang, 2005; Bianchi, 2007) . DAMPs are recognized by receptors for advanced glycosylation end-products (RAGE; Stern et al., 2002) and by toll-like receptors (TLRs; Pisetsky, 2007) .
Recently, TLRs have been identified in human endometrium (Hirata et al., 2005) , decidua (Koga and Mor, 2008) , and in first trimester and term placental human trophoblast, which suggests that the placenta recognizes pathogens or DAMPs through these receptors and induces an immune response (Holmlund et al., 2002) . Stimulation of TLRs present on trophoblasts during the first trimester of human pregnancy increases their ability to recruit innate response cells, modulate the maternal immune system and therefore participate in the pathogenesis of some pregnancy complications (Abrahams et al., 2005) . S100 proteins behave as DAMPs and are found in high levels in eclamptic patients but not in patients with pre-eclampsia and chronic hypertension and pregnancy (Schmidt et al., 2004) . They are secreted by neutrophils and macrophages in response to cellular stress; they have proinflammatory effects and are found in increased levels in inflamed tissue. S100 proteins are secreted through an alternate pathway that avoids the classical Golgi route (Foell et al., 2007) . This secretion mode is typical of factors known as DAMPs, which as intracellular mediators play a role in cellular homeostasis, but turn into harmful inflammatory molecules after being released to the extracellular space as a result of cell damage, infections or inflammation . The ability of these intracellular proteins to be released by damaged, traumatized, or ischemic tissue and then to act as DAMPs, is limited by their rapid tissue oxidation and opsonization (Lotze, Deisseroth, and Rubartelli, 2007) . As these proteins move from a reductive to an oxidative microenvironment, they are denatured. However, outside of the cell, DAMPs may adopt new conformations, or they may alter the redox potential of the extracellular microenvironment, avoiding inactivation mediated by oxidation, and instead, promoting pathology . Further, if extracellular reductive conditions or hypoxic conditions persist, DAMP-provoked inflammation could result . This pertains to preeclampsia where persistent hypoxic conditions are present.
Besides S100 proteins, other molecules may behave as DAMPs, especially the protein HMGB1 (high mobility group box 1), which is present in the nucleus and cytoplasm of almost all cells and is involved in the maintenance of the structure of the nucleosome and in the regulation of gene transcription (Goodwin et al., 1973) . However, in the extracellular microenvironment, HMGB1 activates inflammatory responses by binding to RAGE, TLR2 and TLR4 receptors and mediates various cellular responses including chemotaxis and release of inflammatory cytokines . It is suggested that HMGB1 promotes inflammatory responses in DCs, at least in part, through the induction of TLR4 expression (Tsung et al., 2007) .
A strong nuclear HMGB1 expression has been found in almost all cells in placentas from normal pregnancies; however, women with preeclampsia have a higher expression of cytoplasmic HMGB1 in human decidual cells (Ulrika Holmlund, 2007) . Expression of RAGE receptors is also significantly higher in the placentas of pre-eclamptic women. This increased expression of HMGB1 and RAGE receptors may play an important role in its pathogenesis. Indeed, the onset of different types of pre-eclampsia might be associated with the localization of these receptors to certain cells (Gao, 2008) .
Since both immune system cells and trophoblasts possess TLRs, it can be deduced that the cells have the ability to recognize DAMPs and be modulated by them. Further, trophoblasts might be responding to PAMPs (pathogen-associated molecular patterns) in addition to DAMPs. Some investigators have associated viral infections with placental disorders, e.g. the AAV-2 (adeno-associated virus-2), whose DNA has been more frequently found in trophoblast in cases of severe pre-eclampsia, which might indicate that infection by this virus could lead to placental dysfunction (Arechavaleta-Velasco et al., 2006) . In addition, primary infections or activation of AAV-2 combined with maternal IgM seropositivity in early stages of pregnancy have been associated with pre-eclampsia, stillbirth and preterm birth (Arechavaleta-Velasco et al., 2008) .
Conclusions
Pre-eclampsia is a complex syndrome with a documented pathophysiology that begins very early in gestation. However, its clinical signs do not appear until the second or third trimester. The goal of research, and the purpose of this review, is to identify the likely early events leading to aberrant placentation that are the root causes of pre-eclampsia. Not only will this inform about the progression of the disease, it should identify biomarkers that can be used to predict women at risk, plus provide targets for intervention to diminish the incidence and severity of the problem.
The primary focus of this review was on the immunological events that are, or might be associated with, the origins of pre-eclampsia. A schematic representation of various components of the immune system and their potential interactions and involvement in preeclampsia is described in Fig. 3 .
In the placenta that becomes pre-eclamptic, IFN-g production increases which reduces the trophoblast's invasive capacity through the modulation of metalloproteinases, chemokine receptors and adhesion molecules. Elevated IFN-g synthesis may also shift the balance toward a Th1 phenotype in the pre-eclamptic mother. The source of IFN-g at the placental level may be the uNK cells, but whether they are contributing to the systemic immune shift toward Th1, or specifically participating in the regulation of the placental microenvironment, is uncertain. The additional possibility exists that NK lymphocytes are not inhibited by HLA-G or by the receptors that recognize ILT2 and ILT4. The need to identify which cells or antigens are modulating the immune responses in preeclampsia continues along with the need to clarify the mechanisms involved. Figure 3 Early immunological events leading to pre-eclampsia. IFN-g from uNK and/or Th1 cells in the placenta and TGF-b3 (from unknown sources) are two cytokines that inhibit trophoblast invasion via their arrest of activin-promoted MMP production. Th1 production of IFN-g may be under the regulation of DC (stimulated by DAMPs) or Treg lymphocytes. High levels of IFN-g also inhibit Th2 cells and IL-10 actions. The macrophages (Mw) probably participate in the poor endovascular invasion of the trophoblast observed in pre-eclampsia. At this time, it is unknown whether Th17 cells are associated with the etiology of pre-eclampsia. Green arrows and lines describe progressive events and stimulatory or promoting factors; red lines describe inhibitory factors.
Immune system participates in origins of pre-eclampsia Could the Th1 lymphocyte be the producer of IFN-g in this pathology? It could be possible that this cell might be influenced by cytokine microenvironments or by the placental DCs. Therefore, it is essential to evaluate the cytokine microenvironments at the placental level as well as the characteristics of the DCs both in normal and preeclamptic placentas, since the antigen-presenting DCs may not be tolerogenic and therefore promote Th1 type responses leading to pre-eclampsia.
It is noteworthy that Treg lymphocytes have been found at both normal and reduced levels in pre-eclampsia and apparently do not regulate the Th1/Th2 balance in pre-eclampsia. If true, and we know that PDL deficiency is associated with a shift toward Th1, it raises the question of whether Tregs in pre-eclampsia are deficient in PD-L1. Further, Th17 lymphocytes, or rather the IFN producing the Th17/Th1 subpopulation, might be favoring expression of the Th1 phenotype. If these cells are actually involved, a role for them has not been described in pre-eclampsia. Such a role might be that they are induced through cytokine modulation perhaps from placental DCs.
The antigens or proteins possibly contributing to the Th1 phenotype or the recruitment of immune system cells include the DAMPs, which are recognized by TLRs of DCs, other leukocytes, or the trophoblast itself. Therefore, further research on the role of DAMPs in relation to the origins of pre-eclampsia could prove valuable.
Conversely, it should be stated that not only is IFN-g increased, it also inhibits trophoblast invasion. TGF-b1 and TGF-b3 also inhibit this invasion. Further research is necessary to elucidate the immune system events associated with the origin of pre-eclampsia. Perhaps they evolve by allorecognition of fetal antigens, or by mutations in receptors that regulate immune system responses, or via inflammatory events, such as infections, at the moment that placentation occurs. Regardless, it is now quite clear that the immune system plays a major role in the early responses that alter trophoblast differentiation and function and lead to pre-eclampsia.
